Acceleron Pharma Inc (XLRN)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

128 SIDNEY STREET CAMBRIDGE, MA 02139

Acceleron Pharma, Inc. provides pharmaceutical products. The company focuses on discovering, developing, manufacturing, and marketing of protein therapeutics for cancer and orphan diseases. Acceleron Pharma serves patients throughout the United States.

Data as of 2020-07-04
Market Cap5.455 Billion Shares Outstanding53.825 Million Avg 30-day Volume839.677 Thousand
P/E Ratio Dividend Yield EPS-2.59
Price/Sales113.909 Price cash flow ratio Price free cash flow ratio-50.7
Book Value7.69 Price to Tangible Book12.52 Alpha0.03
Short Interest Ratio % Short Interest to Float R-squared0.036036
BETA0.755997 52-week High/Low110.49 / 37.6 Stddev0.169591
View SEC Filings from XLRN instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 8 4 (0.26%)
13F Filers holding this stock: 213 70 (4.58%)
Aggregate 13F shares on 03/31/2020: 47.069 Million 27.637 Million
Aggregate 13F shares on 12/31/2019: 48.28 Million 28.092 Million
Percent change: -2.51% -1.62%
Funds creating new positions: 64 27
Funds Adding to an existing position: 53 19
Funds closing out their position: 30 18
Funds reducing their position: 76 20
Heat Map Ranking for 03/31/2020 34
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding XLRN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding XLRN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

108.1 Thousand total shares from 1 transactions

Open Market Sells (S)

50 Thousand total shares from 7 transactions

Exercise Derivative Conversion (M)

50 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

DABLE HABIB J CEO AND PRESIDENT

  • Officer
  • Director
89,324 2020-07-01 4

CELGENE CORP /DE/

BRISTOL MYERS SQUIBB CO

  • 10% Owner
6,971,772 2020-07-01 1

SHERMAN MATTHEW L

0 2020-06-23 0

MCGUIRE TERRANCE

  • Director
  • 10% Owner
12,853,817 2020-06-23 0

NADER FRANCOIS

  • Director
0 2020-06-17 1

HITE CHRISTOPHER EVP & VICE CHAIRMAN

  • Officer
70,000 2020-06-15 2

SMITH KAREN L.

  • Director
54,193 2020-06-11 1

GEORGE JEAN

  • Director
0 2020-06-09 1

KEARNEY TERRENCE C

  • Director
0 2020-06-01 1

POPS RICHARD F

  • Director
0 2020-05-29 0

ZAKRZEWSKI JOSEPH S

  • Director
40,000 2020-05-18 2

MCCOURT THOMAS A PRESIDENT

  • Officer
319,847 2020-05-11 1

MCLAUGHLIN KEVIN F

1,750 2020-04-29 5

VENESS ADAM M SVP, GENERAL COUNSEL AND SEC.

  • Officer
21,161 2020-04-08 6

KANGO SUJAY EVP, CHIEF COMMERCIAL OFFICER

  • Officer
15,344 2020-02-13 3

KANIA EDWIN M JR

  • 10% Owner
23,847 2020-01-10 0

QUISEL JOHN D EVP, CHIEF BUSINESS OFFICER

  • Officer
53,316 2020-01-02 2

BACKSTROM JAY T. EVP, RESEARCH AND DEVELOPMENT

  • Officer
0 2020-01-02 3

MALIK KEMAL

  • Director
0 2020-01-02 3

ZELDIN ROBERT K CHIEF MEDICAL OFFICER

  • Officer
0 2019-12-18 0

BRISTOL MYERS SQUIBB CO

  • 10% Owner
6,971,772 2019-11-20 1

KUMAR RAVINDRA SVP & CHIEF SCIENTIFIC OFFICER

  • Officer
86,986 2019-09-10 1

MANIATIS TOM

  • Director
136,731 2019-01-25 0

CELGENE CORP /DE/

6,824,685 2019-01-18 1

ROVALDI CHRISTOPHER SVP, PROGRAM MGMT AND OPS

  • Officer
25,858 2018-04-03 0

ERTEL STEVEN D EVP & CHIEF OPERATING OFFICER

  • Officer
136,977 2017-03-02 0

KNOPF JOHN L CEO AND PRESIDENT

  • Officer
  • Director
214,084 2016-11-09 0

MCGUIRE TERRANCE

POLARIS VENTURE MANAGEMENT CO IV LLC

POLARIS VENTURE PARTNERS ENTREPRENEURS FUND IV LP

POLARIS VENTURE PARTNERS IV LP

  • Director
  • FORMER 10% OWNERFORMER 10% OWNERFORMER 10% OWNER
2,621,738 2014-06-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 S 4,400 $98.57 d 90,424 89,324.00 direct yes

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 S 13,047 $95.85 d 119,577 89,324.00 direct yes

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 M 50,000 $35.04 a 139,324 89,324.00 direct yes

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 M 50,000 d 350,000 89,324.00 direct yes

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 S 9,534 $97.43 d 94,824 89,324.00 direct yes

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 S 3,000 $94.46 d 132,624 89,324.00 direct yes

CELGENE CORP /DE/ - > 10% Owner

BRISTOL MYERS SQUIBB CO - > 10% Owner

2020-07-01 P 108,108 $92.50 a 6,971,772 6,971,772.00 direct

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 S 1,100 $99.42 d 89,324 89,324.00 direct yes

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 S 15,219 $96.49 d 104,358 89,324.00 direct yes

DABLE HABIB J - Director - Officer CEO AND PRESIDENT

2020-07-01 S 3,700 $93.53 d 135,624 89,324.00 direct yes

HITE CHRISTOPHER - Director

2020-06-04 A 10,267 a 10,267 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments